These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10565690)

  • 21. Chemotherapy during pregnancy: what is really safe?
    Peccatori F; Martinelli G; Gentilini O; Goldhirsch A
    Lancet Oncol; 2004 Jul; 5(7):398. PubMed ID: 15231245
    [No Abstract]   [Full Text] [Related]  

  • 22. Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up.
    Barni S; Piazza E; Frontini L; Visini M; Ardizzoia A; Grassi MM; Nosenzo MA; Mandalà M; Biasioli R; Freddi E; Lucani L; Recalcati A; Pravettoni A; Sala R; Rezzani C; Villa S; Trabucchi E;
    Oncology; 2004; 67(1):40-7. PubMed ID: 15459494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
    Lück HJ; Thomssen C; Du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):36-9. PubMed ID: 9516602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
    Hunz M; Jetter A; Warm M; Pantke E; Tuscher M; Hempel G; Jaehde U; Untch M; Kurbacher C; Fuhr U
    Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel plus epirubicin in advanced breast cancer.
    Conte PF; Gennari A; Salvadori B; Pazzagli C; Bengala C
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):40-4. PubMed ID: 9516603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carcinoma en cuirasse of the breast.
    Carlesimo M; Rossi A; De Marco G; Narcisi A; Cacchi C; Mari E; Persechino F; Camplone G
    Eur J Dermatol; 2009; 19(3):289-90. PubMed ID: 19557891
    [No Abstract]   [Full Text] [Related]  

  • 27. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
    Generali D; Fox SB; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield SM; Bruzzi P; Bersiga A; Allevi G; Milani M; Aguggini S; Dogliotti L; Bottini A; Harris AL
    Endocr Relat Cancer; 2006 Sep; 13(3):921-30. PubMed ID: 16954440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer.
    Florescu M; Magda LS; Enescu OA; Jinga D; Vinereanu D
    J Am Soc Echocardiogr; 2014 Jan; 27(1):83-92. PubMed ID: 24268372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer.
    Lüftner D; Wagner K; Dingeldein G; Haas A; Sezer O; Mergenthaler HG; Wernecke KD; Possinger K
    Anticancer Res; 1999; 19(4C):3583-90. PubMed ID: 10629656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer.
    Kaya AO; Coskun U; Buyukberber S; Benekli M; Tekin E; Cifter C; Ozturk B; Yildiz R; Yaman E; Uner A; Yamac D
    J BUON; 2010; 15(2):248-54. PubMed ID: 20658717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin.
    Glück S
    Oncologist; 2005; 10(10):780-91. PubMed ID: 16314288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weekly epirubicin in the treatment of gestational breast cancer (GBC).
    Peccatori FA; Azim HA; Scarfone G; Gadducci A; Bonazzi C; Gentilini O; Galimberti V; Intra M; Locatelli M; Acaia B; Rossi P; Cinieri S; Calabrese L; Goldhirsch A
    Breast Cancer Res Treat; 2009 Jun; 115(3):591-4. PubMed ID: 18712595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neo-adjuvant chemotherapy for breast cancer].
    Shi J; Fang G; Sheng Y
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):423-5. PubMed ID: 11810778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it?
    Ciotti R; Ucci G; Belotti G; Facchi E; Cremonesi M; Gatti C; Baccheta G
    J Clin Oncol; 2001 Nov; 19(22):4269-70. PubMed ID: 11709572
    [No Abstract]   [Full Text] [Related]  

  • 35. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of second-line treatment with high-dose cyclophosphamide in recurrent metastatic breast cancer.
    Hansen F; Møller P; Skovsgaard T
    Cancer Chemother Pharmacol; 1996; 37(4):377-81. PubMed ID: 8548885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of pharmorubicin in cancer of the breast].
    Ass NIa; Borisov VI
    Sov Med; 1986; (10):36-9. PubMed ID: 3544240
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase II study of 4'-epi-doxorubicin in advanced breast cancer.
    Campora E; Nobile MT; Sertoli MR; Rosso R
    Cancer Treat Rep; 1984 Oct; 68(10):1285-6. PubMed ID: 6597003
    [No Abstract]   [Full Text] [Related]  

  • 39. Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer.
    De Rosa L; Lalle M; Perillo A; Pierelli L; Salerno MG; Cortesi E; Martelli O; Pandolfi A; Amodeo R; Marzetti L; Mancuso S; Scambia G
    Anticancer Res; 2001; 21(2B):1367-70. PubMed ID: 11396215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up.
    Ito Y; Mukaiyama T; Ogawa M; Mizunuma N; Takahashi S; Aiba K; Horikoshi N
    Cancer Chemother Pharmacol; 1999; 43(1):8-12. PubMed ID: 9923535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.